Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database

PurposeA chromosomal 1p/19q codeletion was included as a required diagnostic component of oligodendrogliomas in the 2016 World Health Organization (WHO) classification of central nervous system tumors. We sought to evaluate disparities in reported testing for 1p/19q codeletion among oligodendrogliom...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jad Zreik, Panagiotis Kerezoudis, Mohammed Ali Alvi, Yagiz U. Yolcu, Sani H. Kizilbash
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	1p/19q codeletion molecular testing oligodendroglioma oligoastrocytoma disparities adjuvant treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5f92be18a923439d93f50d77c72a2060
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5f92be18a923439d93f50d77c72a2060
record_format	dspace
spelling	oai:doaj.org-article:5f92be18a923439d93f50d77c72a20602021-11-09T06:44:21ZDisparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database2234-943X10.3389/fonc.2021.746844https://doaj.org/article/5f92be18a923439d93f50d77c72a20602021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.746844/fullhttps://doaj.org/toc/2234-943XPurposeA chromosomal 1p/19q codeletion was included as a required diagnostic component of oligodendrogliomas in the 2016 World Health Organization (WHO) classification of central nervous system tumors. We sought to evaluate disparities in reported testing for 1p/19q codeletion among oligodendroglioma and oligoastrocytoma patients before and after the guidelines.MethodsThe National Cancer Database (NCDB) was queried for patients with histologically-confirmed WHO grade II/III oligodendroglioma or oligoastrocytoma from 2011-2017. Adjusted odds of having a reported 1p/19q codeletion test for patient- and hospital-level factors were calculated before (2011-2015) and after (2017) the guidelines. The adjusted likelihood of receiving adjuvant treatment (chemotherapy and/or radiotherapy) based on reported testing was also evaluated.ResultsOverall, 6,404 patients were identified. The reported 1p/19q codeletion testing rate increased from 45.8% in 2011 to 59.8% in 2017. From 2011-2015, lack of insurance (OR 0.77; 95% CI 0.62-0.97;p=0.025), lower zip code-level educational attainment (OR 0.62; 95% CI 0.49-0.78;p<0.001), and Northeast (OR 0.68; 95% CI 0.57-0.82;p<0.001) or Southern (OR 0.62; 95% CI 0.49-0.79;p<0.001) facility geographic region were negatively associated with reported testing. In 2017, Black race (OR 0.49; 95% CI 0.26-0.91;p=0.024) and Northeast (OR 0.50; 95% CI 0.30-0.84;p=0.009) or Southern (OR 0.42; 95% CI 0.22-0.78;p=0.007) region were negatively associated with reported testing. Patients with a reported test were more likely to receive adjuvant treatment (OR 1.73; 95% CI 1.46-2.04;p<0.001).ConclusionDespite the 2016 WHO guidelines, disparities in reported 1p/19q codeletion testing by geographic region persisted while new disparities in race/ethnicity were identified, which may influence oligodendroglioma and oligoastrocytoma patient management.Jad ZreikPanagiotis KerezoudisMohammed Ali AlviYagiz U. YolcuSani H. KizilbashFrontiers Media S.A.article1p/19q codeletionmolecular testingoligodendrogliomaoligoastrocytomadisparitiesadjuvant treatmentNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	1p/19q codeletion molecular testing oligodendroglioma oligoastrocytoma disparities adjuvant treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	1p/19q codeletion molecular testing oligodendroglioma oligoastrocytoma disparities adjuvant treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jad Zreik Panagiotis Kerezoudis Mohammed Ali Alvi Yagiz U. Yolcu Sani H. Kizilbash Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database
description	PurposeA chromosomal 1p/19q codeletion was included as a required diagnostic component of oligodendrogliomas in the 2016 World Health Organization (WHO) classification of central nervous system tumors. We sought to evaluate disparities in reported testing for 1p/19q codeletion among oligodendroglioma and oligoastrocytoma patients before and after the guidelines.MethodsThe National Cancer Database (NCDB) was queried for patients with histologically-confirmed WHO grade II/III oligodendroglioma or oligoastrocytoma from 2011-2017. Adjusted odds of having a reported 1p/19q codeletion test for patient- and hospital-level factors were calculated before (2011-2015) and after (2017) the guidelines. The adjusted likelihood of receiving adjuvant treatment (chemotherapy and/or radiotherapy) based on reported testing was also evaluated.ResultsOverall, 6,404 patients were identified. The reported 1p/19q codeletion testing rate increased from 45.8% in 2011 to 59.8% in 2017. From 2011-2015, lack of insurance (OR 0.77; 95% CI 0.62-0.97;p=0.025), lower zip code-level educational attainment (OR 0.62; 95% CI 0.49-0.78;p<0.001), and Northeast (OR 0.68; 95% CI 0.57-0.82;p<0.001) or Southern (OR 0.62; 95% CI 0.49-0.79;p<0.001) facility geographic region were negatively associated with reported testing. In 2017, Black race (OR 0.49; 95% CI 0.26-0.91;p=0.024) and Northeast (OR 0.50; 95% CI 0.30-0.84;p=0.009) or Southern (OR 0.42; 95% CI 0.22-0.78;p=0.007) region were negatively associated with reported testing. Patients with a reported test were more likely to receive adjuvant treatment (OR 1.73; 95% CI 1.46-2.04;p<0.001).ConclusionDespite the 2016 WHO guidelines, disparities in reported 1p/19q codeletion testing by geographic region persisted while new disparities in race/ethnicity were identified, which may influence oligodendroglioma and oligoastrocytoma patient management.
format	article
author	Jad Zreik Panagiotis Kerezoudis Mohammed Ali Alvi Yagiz U. Yolcu Sani H. Kizilbash
author_facet	Jad Zreik Panagiotis Kerezoudis Mohammed Ali Alvi Yagiz U. Yolcu Sani H. Kizilbash
author_sort	Jad Zreik
title	Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database
title_short	Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database
title_full	Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database
title_fullStr	Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database
title_full_unstemmed	Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database
title_sort	disparities in reported testing for 1p/19q codeletion in oligodendroglioma and oligoastrocytoma patients: an analysis of the national cancer database
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/5f92be18a923439d93f50d77c72a2060
work_keys_str_mv	AT jadzreik disparitiesinreportedtestingfor1p19qcodeletioninoligodendrogliomaandoligoastrocytomapatientsananalysisofthenationalcancerdatabase AT panagiotiskerezoudis disparitiesinreportedtestingfor1p19qcodeletioninoligodendrogliomaandoligoastrocytomapatientsananalysisofthenationalcancerdatabase AT mohammedalialvi disparitiesinreportedtestingfor1p19qcodeletioninoligodendrogliomaandoligoastrocytomapatientsananalysisofthenationalcancerdatabase AT yagizuyolcu disparitiesinreportedtestingfor1p19qcodeletioninoligodendrogliomaandoligoastrocytomapatientsananalysisofthenationalcancerdatabase AT sanihkizilbash disparitiesinreportedtestingfor1p19qcodeletioninoligodendrogliomaandoligoastrocytomapatientsananalysisofthenationalcancerdatabase
_version_	1718441200143302656

Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database

Ejemplares similares